CD40 Activation Protects Dendritic Cells from Anticancer Drug-Induced Apoptosis
CD40 Activation Protects Dendritic Cells from Anticancer Drug-Induced Apoptosis
- Jae-Yeon Jun Hong-Gu Joo
- 대한생리학회-대한약리학회
- The Korean Journal of Physiology & Pharmacology
- 제7권 제5호
- 등재여부 : KCI등재
- 2003.01
- 255 - 259 (5 pages)
Dendritic cells (DCs) play a critical role in various immune responses involving CD4<SUP>⁢</SUP> T cells and have been used to generate anti-tumor immunity. Chemotherapy induces severe side effects including immunosuppression in patients with cancer. Although immunosuppression has been studied, the effects of anticancer drugs on DCs are not fully determined. In this study, we demonstrated that CD40 activation strongly protected DCs from 5-fluorouracil (5-FU) or mitomycin C-induced apoptosis. DC- specific surface markers, including CD11c and major histocompatibility complex (MHC) class II, were used for identifying DCs. CD 40 activation with anti-CD40 mAb significantly enhanced the viability of DCs treated with 5-FU or mitomycin C, assayed by MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide). Fluorescence staining and analysis clearly confirmed the enhancing effect of anti-CD40 mAb on the viability of DCs, suggesting that CD40 activation may transduce critical signals for the viability of DCs. Annexin V staining assay showed that CD40 significantly protected DCs from 5-FU or mitomycin C-induced apoptosis. Taken together, this study shows that CD40 activation with anti-CD40 mAb has strong anti-apoptosis effect on DCs, suggesting that CD40 activation may overcome the immunosuppression, especially downregulation of number and function of DCs in chemotherapy- treated cancer patients.